United States: Capitol Hill Healthcare Update June 26, 2017

Searching for 50 Votes: Changes to Health Bill, CBO Score Coming This Week

Senate Republican leaders are expected to make a series of changes to the healthcare legislation released Thursday as they scramble to gain the support of at least 50 lawmakers in a showdown vote scheduled for later this week.

GOP leaders are expected to offer additional changes on Medicaid, continuous coverage and opioid addiction funding in an effort to entice senators, including five lawmakers who announced their outright opposition and several others who expressed reservations about the draft bill. The Congressional Budget Office also is expected to release its analysis as soon as today, including estimates on insurance coverage and premiums, and the draft bill's impact on government spending.

Senate Majority Leader Mitch McConnell (R-Ky.) this week will try to strike just the right balance of legislative changes to woo moderates and conservatives who oppose the current draft, now called the Better Care Reconciliation Act. It's a tightrope exercise, and it's not clear whether McConnell can succeed. He can only afford to lose two votes from his 52-seat majority.

The Senate will take a procedural vote Wednesday to bring up the bill and then debate the legislation for up to 20 hours, split evenly between the two parties. After that, senators will begin a "vote-a-rama," a series of rapid-fire votes on dozens of amendments in a marathon session that likely could stretch for hours.

GOP leaders will offer their changes to the House-approved bill as one package, called a "manager's amendment." Democrats are expected to offer a series of amendments designed to draw political blood from Republicans, on issues such as restoring insurance regulations and addressing prescription drug prices. Many amendments will never see a vote because the Senate parliamentarian is expected to rule them ineligible to be added to a budget reconciliation bill, which generally can include only provisions that directly impact government spending and taxes.

Will Republicans get the votes they need to pass the bill? That's not currently clear. Some senators who have expressed opposition are expected to ultimately vote for the bill after their policy or state-specific issues are addressed in the manager's amendment. But several key senators say their issues can be addressed only in ways that may undermine the coalition McConnell is trying to assemble.

Will the vote occur this week as McConnell has pledged? All signs point to a vote at the end of the week, even if Republicans don't have the support to pass their revised bill. Some senators, including Sens. Ron Johnson (R-Wis.) and Susan Collins (R-Maine), have said a vote should be delayed until after the Fourth of July recess to allow lawmakers time to understand the bill and its implications – or for additional legislative tweaks and arm-twisting by GOP leaders. But some Republican leadership aides say delaying a vote until mid-July likely wouldn't improve its prospects.

No Democrat is expected to support the bill. But some Republicans speculate that if Sen. Shelly Moore Capito (R-W.Va.) can be persuaded to vote for the bill with certain Medicaid changes and a dramatic boost to opioid addiction funding, Sen. Joe Manchin (D-W.Va.) might vote for it too. Manchin, who has given no public indication he would support the bill, is seeking re-election in 2018 in a state where President Donald Trump received 69 percent of the vote last November.

FDA User Fee Renewal Stalled Until July

With the focus in the Senate on securing votes for Republicans' plans to replace the Affordable Care Act, action on renewing expiring Food and Drug Administration (FDA) user fees is likely to slip until after Congress' Fourth of July recess.

House and Senate committees have approved a five-year renewal of user fees for pharmaceutical and medical device manufacturers, but neither chamber has voted on their bills. Congressional leaders are seeking to avoid a conference committee by harmonizing the legislation before it passes the House and Senate.

The bills that won approval in the Senate HELP and House Energy and Commerce committees do have some differences. But leaders have worked to keep both bills free from controversial language, and committee staff say the differences shouldn't stand in the way of reaching an agreement.

The user fees expire Sept. 30. Without congressional action by Aug. 1, mandatory notices will be sent to FDA staff whose jobs are tied to user fee funding, warning of potential layoffs if Congress fails to renew the program. Lawmakers in both parties say they want to avoid triggering those notices.

Lawmakers Call on VA to Address Payment Backlog

A group of House Republicans is calling on the Department of Veterans Affairs (VA) to address the "alarming amount of late payments" for medical devices in the VA system.

Rep. Jim Banks (R-Ind.) is circulating a draft letter among his colleagues to VA Secretary David Shulkin. Banks, a member of the House Committee on Veterans' Affairs, is planning to finalize the letter this week but so far has nearly four dozen lawmakers who have agreed to sign on.

Banks said some medical device manufacturers have outstanding VA invoices going back as far as 2013, with accounts receivable reaching into the millions of dollars. He said the VA is routinely more than 90 days late on more than one-third of payments for medical devices used in VA healthcare.

Overall, the VA owes as much as $15 million for replacement knees, replacement hips, spine implants, cardiac pacemakers and defibrillators provided through the VA Prosthetics Program, according to the letter.

Republican, Democrat Question Pharma, Insurers on Insulin Costs

The leaders of the Congressional Diabetes Caucus say they are "gravely concerned" about the rising cost of insulin, and they are calling on trade associations representing pharmaceutical manufacturers and insurers to meet with the caucus next month.

Reps. Tom Reed (R-N.Y.) and Diana DeGette (D-Colo.), the co-chairs of the caucus, said the average price of insulin tripled between 2002 and 2013, and many patients are facing high payments due to high deductibles, co-insurance and formulary exclusions.

They requested meetings on July 28 with the Pharmaceutical Research and Manufacturers of America, the Pharmaceutical Care Management Association and America's Health Insurance Plans. The lawmakers said Congress may need to step in to stabilize insulin prices but first they want to hear from stakeholders.

Lawmakers Call for Relief from DME Competitive Bidding

More than 150 House lawmakers are calling on the U.S. Department of Health and Human Services (HHS) to provide relief from the Center for Medicare and Medicaid Services' (CMS') recently enacted competitively bid rates in rural areas for durable medical equipment.

In a letter to HHS Secretary Tom Price, the lawmakers said CMS' action is coming at the expense of Medicare beneficiaries and shifting costs to institutional and clinical care.

Sent by a group led by House Republican Conference Chairwoman Cathy McMorris Rodgers (R-Wash.), the letter calls on Price to provide relief for non-competitive bid areas, which are primarily rural communities. The lawmakers also call for changes to the overall program before the next scheduled round of competitive bidding in 2019.

When he served in the House, Price was an outspoken opponent of DME competitive bidding.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions